The 5th edition of the International HBV Cure Workshop featured the world's most prominent and distinguished speakers that discussed the most current and trending issues in the field. 


 Wednesday 7 November

 Session 1: Modulating approved therapies to achieve HBV Cure
 8:05What is the cure rate with current therapies?
Harry Janssen
Toronto General Hospital / University Health Network, Toronto, Canada
 8:20Stopping Nucleos(t)ide Analogues:  When is it beneficial, when is it dangerous? 
Thomas Berg
University of Leipzig, Germany
 8:35Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies.
Andre Boonstra
Erasmus Medical Center, Rotterdam, The Netherlands
 Session 2: New Endpoints and Biomarkers
 10:00What are the pros and cons of HBsAg loss as the endpoint for treatment?
Jordan Feld
Toronto Centre for Liver Disease, Toronto, Canada
 10:15Can we measure (activity of) cccDNA in the blood?
Massimo Levrero
INSERM, Lyon, France
 10:30Will HBsAg depletion restore HBV specific immunity?
Adam Gehring
Toronto Centre for Liver Disease, Toronto, Canada
 Session 3: Update on Immune Targets for HBV Therapy 
 11:35Rationale for modulating innate immunity: TLR, RIG- and others.
Mala Maini
University College London, London, UK
 11:50Antiviral effect of the RIG-I agonist, Inarigavir
Nezam Afdahl
Beth Israel Deaconess Medical Center, Boston, USA
 12:00Activating Toll-like receptor (TLR)-8 with GS-9688 for HBV therapy
Simon Fletcher 
Gilead Sciences, Foster City, USA
 12:10Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model
Lu Gao
Roche Innovation Center Shanghai, Shanghai, China 
 12:20Innate activation with Inactivated parapox viruses for HBV therapy - AIC649
Daniela Paulsen
AiCuris, Germany
 13:30Rationale for Modulating Adaptive Immunity: Therapeutic Vaccination, Checkpoint Inhibitor and others
Robert Thimme
University of Freiburg, Freiburg, Germany
 13:45Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection
Daniel Verdon
University of Auckland, Auckland, New Zealand
 Session 4: Update on Virologic Targets for HBV Therapy
 15:15Rationale for different Virological Targets in HBV
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
 15:30Clinical progress of the entry inhibitor Myrcludex B
Stephan Urban
University of Heidelberg, Heidelberg, Germany
 15:45Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy
Andrew Vaillant
Replicor, Montreal, Canada
 15:55Clinical update on reducing HBV virus and antigen production using RNAi
Bruce Given,
Arrowhead, Pasadina, USA
 16:05Clinical update, antiviral effect and mode of action of capsid assembly modulators
Jeysen Yogaratnam
Janssen Biopharma, South San Francisco, USA
 16:15Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates
Rich Colonno,
Assembly Bioscience, San Francisco, USA
 17:00Closure of the Workshop